Overview
AMLX market data
Price History
AMLX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.53 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.19 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -94.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $7.63 – $24.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.5B · P/B 4.35 · P/S 12.75.
Company News
Amylyx Pharma shares are trading higher despite reporting weak Q2 results. The market may be looking ahead to a pivotal Phase 3 LUCIDITY trial data readout, with strong cash reserves and clear regulatory strategy reducing risk and fueling optimism.Benzinga · Aug 6, 2026, 6:21 PM
RAmylyx Pharma Q2 EPS $(0.39) Misses $(0.36) Estimate, Cash & Equivalents $279.8M. Cash runway Expected To Fund Operations Till 2028Benzinga · Aug 6, 2026, 11:06 AM
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $26Benzinga · Aug 3, 2026, 7:35 PM
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $24Benzinga · Jul 20, 2026, 11:34 AM
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $40Benzinga · Jun 25, 2026, 2:15 PM
Amylyx Pharma To Present Data From First-In-Human, Dose-Ranging Phase 1 LUMINA Trial Of AMX0114 At ENCALS Meeting 2026Benzinga · Jun 23, 2026, 11:15 AM
CORRECTION: Amylyx Pharmaceuticals Announced Results From Phase 2 Open-Label HELIOS Clinical Trial Of AMX0035 On May 15Benzinga · May 22, 2026, 12:05 PM
Amylyx Pharmaceuticals Publishes Data From Weeks 24, 48 Of Its Phase 2 HELIOS Study Of AMX0035 To Treat Wolfram Syndrome; Results Demonstrate Continued Improvements In Pancreatic Beta Cell Function Through Week 48Benzinga · May 15, 2026, 4:19 PM